On page 10 you can find the article by The Parliament Magazine in which Dr. Isabel Varela-Nieto, Patrick D’Haese, Michael Paillasse and Josef Syka talk about our project
Academia and industrial researchers are working hand in hand in TARGEAR to better understand the aetiology of this disorder and find therapies which combine pharmaceuticals and hearing devices.
TARGEAR is a Marie Curie Industry-Academia Partnerships and Pathways action supported by the FP7-PEOPLE program, with a duration of four years (2014-2017).
The TARGEAR project is comprised of experienced research groups in complementary fields ranging from molecular to clinical
aspects of ARHL.
UNIFI is interested in the use of in vitro models that help us to better understand the biology of inner ear sensory cells and investigate the factors that could prevent or restore hearing loss.
BIOMED and CSIC, in collaboration with La Paz Hospital, are focused on the study of in vivo animal models for hearing loss and on developing bench to bedside strategies. For people affected by hearing loss, hearing implant systems are often the only technology capable of restoring their hearing, thereby significantly enhancing patients’ quality of life. Over 300,000 people worldwide have received a cochlear implant (CI), which is a surgically implanted electronic device that provides an almost natural acoustical experience for a deaf person.
MED-EL is a pioneer in this field. In 1977, MED-EL founders Drs. Ingeborg and Erwin Hochmair developed the world’s first micro-electronic multichannel CI. Today, MED-EL continues to set new standards in the development of innovative hearing implant solutions by fostering interaction with basic and clinical researchers.
AFFICHEM is developing drug candidates to prevent or recover from auditory neuronal degeneration.